

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4720386

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ACTION MEDICINES, S.L.	11/15/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AMDERMA PHARMACEUTICALS, LLC
<b>Street Address:</b>	995 ROUTE 202/206
<b>City:</b>	BRIDGEWATER
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08807
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15455844
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	lmurphy@dsiplaw.com
<b>Correspondent Name:</b>	SERVILLA WHITNEY LLC
<b>Address Line 1:</b>	33 WOOD AVENUE SOUTH
<b>Address Line 2:</b>	SUITE 830
<b>Address Line 4:</b>	ISELIN, NEW JERSEY 08830
<b>ATTORNEY DOCKET NUMBER:</b>	AMD0003-04CT
<b>NAME OF SUBMITTER:</b>	DONNA R. FUGIT
<b>SIGNATURE:</b>	/Donna R. Fugit, Reg. #32135/
<b>DATE SIGNED:</b>	12/06/2017
<b>Total Attachments: 11</b>	
source=00706757#page1.tif	
source=00706757#page2.tif	
source=00706757#page3.tif	
source=00706757#page4.tif	
source=00706757#page5.tif	
source=00706757#page6.tif	

source=00706757#page7.tif  
source=00706757#page8.tif  
source=00706757#page9.tif  
source=00706757#page10.tif  
source=00706757#page11.tif

## PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), dated as of 15<sup>th</sup> November, 2011, is made and entered into by and between Action Medicines, S.L., a company organized under the laws of Spain ("Assignor"), and AmDerma Pharmaceuticals, LLC, a Delaware limited liability company ("Assignee"). Unless otherwise defined herein, all capitalized terms used in this Assignment shall have the meanings set forth in that certain Purchase Agreement, dated as of 15<sup>th</sup> November, 2011 (the "Purchase Agreement"), by and among Assignor, DermAct Pharmaceutical, Inc., a Delaware corporation ("DermAct") and Assignee.

WHEREAS, concurrently with the execution and delivery of this Assignment, Assignor, DermAct and Assignee are consummating the transactions contemplated by the Purchase Agreement.

NOW, THEREFORE, for good and valuable consideration as listed in detail in Section 4 of the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Assignment. In accordance with and subject to the terms and conditions of the Purchase Agreement, Assignor does hereby acknowledge that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto Assignee, its successors, legal representatives, and assigns, Assignor's entire right, title, and interest throughout the world in, to, and under the patents and patent applications listed in Exhibit A attached hereto (the "Patents and Patent Applications"), including without limitation all patents and patent applications claiming priority to and/or benefit of the Patents and Patent Applications including but not limited to divisions, continuations, and continuations-in-part thereof and all reissues, reexaminations, and extensions thereof, and all priority rights under the International Convention for the Protection of Industrial Property for every member country, and all applications for patents (including without limitation related rights such as utility-model registrations, registrations, inventor's certificates, and the like) heretofore or hereafter filed in any country/countries foreign to the United States, and all patents (including all extensions, renewals and reissues thereof) granted for in any country/countries foreign to the United States. In addition, Assignor does hereby sell, assign, transfer and convey to Assignee, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to Assignee, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said patents and patent applications before or after issuance. Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks, and any officials of countries foreign to the United States whose duty is to issue patents on applications as aforesaid, to issue all Letters Patents resulting from the Patents and Patent Applications in the name of Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.

2. Further Assurances. AM further agrees that it will at any time and from time to time, at the request of AmDerma, execute and deliver to AmDerma all other and further instruments reasonably necessary to vest in AmDerma the right, title and interest in the Patent which this instrument purports to transfer to AmDerma.

2. Limitation. Notwithstanding anything to the contrary contained herein, the Assignee does not hereby assume or agree to perform or pay any liabilities or obligations of either Assignor that are not Assumed Liabilities.

3. Amendments. This Assignment may only be amended by a writing signed by each Assignor and Assignee.

4. Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute a single document.

5. Delivery Pursuant to Purchase Agreement. Notwithstanding anything to the contrary herein, Assignor and Assignee is executing and delivering this Assignment in accordance with and subject to all of the terms and provisions of the Purchase Agreement. To the extent of any conflict between the terms and conditions of this Assignment and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall govern, supersede and prevail.

6. Binding Effect. This Assignment shall be binding upon, and shall inure to the benefit of, Assignors and Assignee and their respective successors and assigns.

7. Governing Law. This Assignment shall be governed by and construed in accordance with the laws of the State of New Jersey, without regard for conflicts of laws principles.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, this Assignment has been duly executed and delivered by the parties hereto as of the date first above written.

ASSIGNOR:

ACTION MEDICINES, S.L.

By: 

Name: Santiago de Gracia

Title: CEO-Consejero Delegado

Sign in presence of a Notary and have  
Notary attach Acknowledgement

ASSIGNEE:


AMDERMA PHARMACEUTICALS, LLC

By: 

Name: Chirag Patel

Title: Manager and President

Sign in presence of a Notary and have  
Notary attach Acknowledgement

  
\_\_\_\_\_  
Attorney at Law / State of NJ  
Anshu Pathak, Esq.

... T I M A C I O N : -----

YO, MIGUEL KRAUEL ALONSO, Notario de Málaga, Ilustre Colegio de Andalucía . -----

VISTA Y LEGITIMADA: Doy fe que la firma y rúbrica que precede de DON SANTIAGO DE GRACIA CLEMENT con D.N.I./N.I.F. número 00100848-Q, la considero legitima por haber sido puesta a mi presencia y haberle identificado por su reseñado documento, que me exhibe y le devuelvo.-

En Málaga, a veintitrés de septiembre de dos mil once .


APLICACION ARANCEL LEY DE TASAS

HONORARIOS: 6,16 €

LIBRO INDICADOR: Hoja N° 2609

Section 2ª

FE PÚBLICA  
NOTARIAL



*[Handwritten signature]*

**EXHIBIT A**  
**TO**  
**PATENT ASSIGNMENT**

*(See Attached)*

COMPOUND PATENTS

Ref. No.	Title of Invention	Country	Status	Appln. No.	Filed	Patent No.	Issued
2021	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenic Diseases such as Cancer and Psoriasis	US	Response to non-final OA filed 6/30/2010 awaiting to PTO action	10/588,166	8/2/2006 PCT Filing Date 2/16/2005 Priority 2/16/2005 (PCT Filing) 2/17/2004	US20080293816 Pub. date 11/27/2008	
P2280 3BEB P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Belgium	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2280 3DBE P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Germany	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2280 1DKE P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Denmark	Granted Validated	EP05708114 3	16/02/2005	EP1719509 DK1EP1719509 T3	
P2280 3ES0 Q	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Spain	Granted	P200400371 5	17/02/2004	ES2238924AB	
P2280 3ESE P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Spain	Granted Validated	EP05708114 3	16/02/2005	EP1719509 ES2334447E3	
P2280 3FRE P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	France	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2280 3GBE P	Use of Dihydroxy-benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	United Kingdom	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2280 3IEE P	Use of Dihydroxy-benzenesulfonic acids in the Production of	Ireland	Granted Validated	EP05708114 3	16/02/2005	EP1719509	

4/741524561



COMPOUND PATENTS

	Medicaments for Angiogenesis-dependent Diseases						
P2280 3ITE P	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Italy	Granted Validated	EP05708114 3	16/02/2005	EP1719509 47515BE2010	
P2280 3MEE P	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Netherlan ds	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2280 3ITE P	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Portugal	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2803 SEEP	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Sweden	Granted Validated	EP05708114 3	16/02/2005	EP1719509	
P2803 AUP C	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Australia		2005211956	16/02/2005		
P2803 CAP C	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Canada		2,555,246	16/02/2005		
P2803 CNP C	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	China		2005800051 87.3	16/02/2005	CN101014330A	
P2803 ILPC	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Israel		177238	16/02/2005		
P2803 JPPC	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for	Japan		2006-53602	16/02/2005		

0741574561

COMPOUND PATENTS

	Angiogenesis-dependent Diseases						
P2803 MXP C	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Mexico	Granted	PAMA 2006 099295	16/02/2005	269609	
P2803 UAP C	Use of Dihydroxybenzenesulfonic acids in the Production of Medicaments for Angiogenesis-dependent Diseases	Ukraine	Granted	2006 09127FM	16/02/2005	86399	
2022	Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the Treatment of Cancer, Rosacea and Psoriasis	US	Response to Final Office Action and RCE filed 12/28/2009 awaiting PTO action	11/506,469	8/16/2006 CIP of 10/588,166 above filed 8/2/2006 (Nat Phase Filing) 2/16/2005 (PCT Filing) 2/17/2004	US20070149418 Pub.date 6/28/2007	
202	Use of Dihydroxybenzenesulfonic derivatives for Treating Actinic Keratosis	US	Notice of Appeal filed 4/15/2010 Response to final OA and RCE due 10/15/2010 (6/7) FINAL deadline 11/15/2010 7/7)	11/839,508	8/15/2007 8/16/2006 and CIP of 11/506,469 above filed 8/16/2006 which is CIP of 10/588,166 above filed 8/2/2006 (Nat Phase Filing) 2/16/2005 (PCT Filing) 2/17/2004	US20080125485 Pub.date 5/29/2008	
2023	Methods of use for 2,5-dihydroxybenzene sulfonic acid Compounds for the Treatment of Cancer, Rosacea and Psoriasis	US	Pending awaiting PTO action	12,257,854	Divisional of 11/506,469 above filed 8/16/2006 which is a CIP of 10/588,166 above filed 8/2/2006 (Nat Phase Filing) 2/16/2005	US20090111779 Pub.date 4/30/2009	

K/74 (5/24/06)

COMPOUND PATENTS

					PCI Filing Date 2/17/2004		
P3195 EPEC	Use of Dihydroxy- benzenesulfonate derivatives for treating Actinic Keratosis	EU		EP07788425	8/13/2007	EP2054051	

A74152454.1

COMPOUND PATENTS

Ref. No.	Title of Invention	Country	Status	Appln. No.	Filed	Patent No.	Issued
203	Use of Dihydroxybenzenesulfonic derivatives for Treating Dermatitis	US	Final OA mailed 7/1/2010 Response to final OA 19/1/2010 (3/6) Final deadline 1/1/2011 (6/6)	11/839,512	8/16/2006 7/2/2007	US20080114075 Pub. date 5/15/2008	
P319 6EP PC	Use of Dihydroxybenzenesulfonic derivatives for Treating Dermatitis	EU		EP07788426.0	8/15/2007	EP2056815	
204	Use of 2,5-dihydroxybenzene compounds and Derivatives for the Treatment of Rosacea	US	Final OA mailed 5/5/2010 Response to final OA and RCE 10/5/2010 (5/6) Final deadline 11/5/2010 (6/6)	11/839,515	8/16/2006 7/2/2007	US20080113947 Pub. date 5/15/2008	
P319 8EP PC	Use of Dihydroxybenzenesulfonic derivatives for the Treatment of Rosacea	EU		EP07788428.6	8/15/2007	EP2056813	
205	Use of 2,5-dihydroxybenzene compounds and Derivatives for the Treatment of Psoriasis	US	Final OA mailed 8/21/2010 Response to final OA and RCE 10/21/2010 (5/6) Final deadline 11/21/2010 (6/6)	11/839,520	8/16/2006 7/2/2007	US20080113943 Pub. date 5/15/2008	
P319 9EP PC	Use of Dihydroxybenzenesulfonic derivatives for the Treatment of Psoriasis	EU		EP07788429.4	8/15/2007	EP2056814	
206	Use of 2,5-dihydroxybenzene compounds and Derivatives for the Treatment of Skin Cancer	US	Response filed 7/26/2010 awaiting PTO action	11/839,522	8/16/2006 7/2/2007	US20080114060 Pub. date 5/15/2008	

4/24/2008

**COMPOUND PATENTS**

210	Skin Penetration Enhancing Systems for Polar Drugs	US	Pending (National Stage Entered 8/16/2010)	12/867,875	Filing date 2/17/2009 Priority 2/15/2008 (US Provisional)	NA
212	Processes for the Preparation of 2,3-dihydroxybenzene sulfonic Acid Salts	US	Pending (National Stage Entered 7/2/2010)	12/811,621	Priority 1/3/2008 Filing date 1/2/2009	NA

07415246c1